Current Concepts In Treating Acute Charcot's Arthropathy

Author(s): 
By Lee C. Rogers, DPM, Nicholas J. Bevilacqua, DPM, and David G. Armstrong, DPM, PhD

Final Notes

     Future directions for treating Charcot’s arthropathy are clear. There is still a need for more treatments that are designed to interrupt the natural history of the disease process. We must gain a more complete understanding of the pathophysiology of Charcot’s arthropathy at the biochemical level. As the governments of the world are recognizing diabetic foot disorders as a large financial burden, the funding of research will likely increase. Subsequently, more high quality trials will be initiated and physicians will be able to offer more effective treatments to those who suffer from Charcot foot. Dr. Armstrong is a Professor of Surgery, Chair of Research and Assistant Dean at the William M. Scholl College of Podiatric Medicine at Rosalind Franklin University of Medicine in Chicago. He is the Director of the Center for Lower Extremity Ambulatory Research (CLEAR) at the aforementioned university and is the Co-Chair of the Diabetic Foot Global Conference (DFcon.com). Dr. Rogers is a Research Fellow at the Center for Lower Extremity Research (CLEAR) at the William M. Scholl College of Podiatric Medicine at Rosalind Franklin University of Medicine and Science. Dr. Bevilacqua is a Fellow at CLEAR. He is also a Fellow at the National Center for Limb Preservation. Dr. Steinberg (shown) is an Assistant Professor in the Department of Plastic Surgery at the Georgetown University School of Medicine in Washington, D.C. He is a Fellow of the American College of Foot and Ankle Surgeons.
 

 

Add new comment